Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

eli lilly nederland b.v. - duloksetin hidroklorid - urinarna inkontinenca, stres - psychoanaleptics, - zdravilo yentreve je indicirano za ženske za zdravljenje zmerne do hude stalne urinske inkontinence (sui).

Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

molmed spa - alogenskih t celice, gensko spremenjene z retrovirusni vektor kodiranje za skrajšani obliki ljudi nizko afiniteto živca rastni faktor receptor (Δlngfr) in herpes simplex virus timidin-kinazo (hsv-tk mut2) - hematopoietic stem cell transplantation; graft vs host disease - antineoplastična sredstva - zalmoxis je indiciran kot dodatno zdravljenje pri haploidentični hematopoetski presaditvi matičnih celic (hsct) pri odraslih bolnikih z visokim tveganjem hematoloških malignomov.

Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - artritis, revmatoidni - imunosupresivi - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). zdravilo olumiant se lahko uporablja kot monoterapija ali v kombinaciji z metotreksatom. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

fondazione telethon ets - avtologni cd34 + obogaten del celice, ki vsebuje cd34 + celice transduced retrovirusni vektor, ki kodira za ljudi adenozin deaminase (ada) zaporedje cdna iz človeške krvotvornih matičnih/matičnih (cd34 +) celic - huda kombinirana imunska pomanjkljivost - immunostimulants, - strimvelis je indicirano za zdravljenje bolnikov z huda kombinirane imunske pomanjkljivosti zaradi pomanjkanja adenozin deaminase (ada-hu), za katere ni primeren človeških levkocitov antigenov (hla)-ujema povezanih izvornih celic darovalca je na voljo (glej oddelek 4. 2 in oddelek 4.

Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

eli lilly nederland b.v. - tadalafil - erektilna disfunkcija - urološki - zdravljenje erektilne disfunkcije pri odraslih samcih. za učinkovitost tadalafila je potrebna spolna stimulacija. tadalafil lilly ni označeno za uporabo žensk. zdravljenje znakov in simptomov benigna hiperplazija prostate pri odraslih moških.

Slovēnija - slovēņu - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

eli lilly regional operations gmbh -

Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

eli lilly nederland b.v. - abemaciclib - neoplazme dojke - antineoplastična sredstva - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

eli lilly nederland b.v. - galcanezumab - bolezni migrene - analgesics, galcanezumab - emgality je primerna za preventivo migrena pri odraslih, ki imajo vsaj 4 migrenskih dni na mesec.

Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - antineoplastična sredstva - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.

Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

pfizer europe ma eeig  - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.